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Background
Protease inhibitors based antiretroviral therapy has been
associated with elevated plasma insulin levels and insulin
resistance. HCV infections are an independent risk factor
for diabetes development. In vitro Atazanavir (ATV) has
shown minimal inhibitory effect on the insulin-regulated
glucose transporter GLUT4. Studies in healthy HIV-nega-
tive demonstrated a favorable metabolic profile. Clinical
studies in HIV and HCV/HIV coinfected pretreated
patients with underlying real conditions are needed.
Methods
51 pretreated HIV-1 infected patients who started ATV/r
were included prospectively. Insulin resistance was assessed
by HOMA (Homeostasis Model Assesment). Hepatotoxi-
city was defined according to AIDS Clinical Trials Group
criteria to ALT values. Clinical data and laboratory para-
meters were analyzed at baseline and every 12 weeks up to
48. It includes body mass index (BMI), fasting glucose,
insulin, triglycerides (TG), total cholesterol (TC), low-den-
sity lipoprotein-cholesterol (LDL-c), CD4+ cell count and
HIV-1 RNA. HIV monoinfected and HIV/HCV co-infected
(pos HCV-RNA) patients were compared.
Results
23 HIV-mono and 28 HIV-HCV coinfected patients were
analyzed. Mean age was 40 ± 8 years, male 74%; median
CD4 count (IQR) 288 (224-548) cells/μL. 53% plasma
HIV-RNA<50 copies/mL. Only 1 case of severe hepato-
toxicity (Grade 4) was seen (coinfected patient). Metabolic
profile is shown in Table 1. ATV was discontinuated in 4
cases (2 poor adherence and 2 gastrointestinal intoler-
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Table 1
HCV BASAL 48-WEEK Δw48-w0 P(Δw48-w0)
BMI (Kg/m
2) - 24.5 (22-27) 26 (23-29) 0.34 (-1.0-+0.9) >.05
+ 22 (20-26) 20 (18-23) -0.35 (-0.8-+1.2) >.05
Fasting glucose (mg/dl) - 87 (83-97) 88 (85-95) -0.5 (-5.7-+8) >.05
+ 94 (83-103) 90 (80-105) +2 (-24-+12) >.05
HOMA - 1 (0.8-3.6) 1.4 (0.9-3.2) -0.06 (-1.5-+0.8) >.05
+ 3.5 (1.8-6.3) 4.5 (3-7.5) +1.8 (-4.6-+3.1) >.05
TC (mg/dl) - 197 (165-215) 179 (161-200) -18 (-40- -3) .02
+ 157 (132-174) 144 (127-165) -5 (-32-+15) >.05
TG (mg/dl) - 149 (122-241) 126 (101-208) -10 (-92-+17) >.05
+ 139 (99-186) 114 (89-197) 0 (-19-+59) >.05
As Median (Interquartile range). In all comparisons between HCV- vs HCV+ p > .05
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documented.
Discussion
ATV/r can be safely used in patients with chronic viral
hepatitis. ATV/r regimens do not induce insulin resis-
tence and has a good lipid profile in coinfected as in
monoinfected patients. These results would be better
with unboosted ATV regimens.
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